top of page
Pulp Fixin™
Blog Post
What’s Next for Cold Chain in Biotech and Pharma? Expect the Styrofoam Crackdown.
As the global demand for biologics, mRNA therapies, and temperature-sensitive pharmaceuticals accelerates, the cold chain infrastructure that supports them is under increasing scrutiny—not just for performance, but for environmental impact. While 2026 promises smarter systems, tighter regulations, and expanded global distribution, there’s one constant still clinging to the supply chain: Styrofoam. 📦 The Problem with Performance—Isn’t Performance Expanded polystyrene (EPS), k
2 min read
Automation Meets Sustainability: Can Labs Have Both?
In the evolving landscape of biotech research, automation has become indispensable for enhancing efficiency and throughput. However, this...
2 min read
bottom of page